Production (Stage)
Cadrenal Therapeutics, Inc.
CVKD
$13.70
-$0.16-1.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 100.23% | 203.78% | 86.49% | 54.52% | 16.72% |
| Depreciation & Amortization | 816.67% | -33.33% | -33.33% | -16.67% | 200.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.74% | 238.53% | 115.30% | 140.36% | -58.20% |
| Operating Income | -123.74% | -238.53% | -115.30% | -140.36% | 58.20% |
| Income Before Tax | -131.19% | -265.99% | -132.30% | -138.58% | 67.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -131.19% | -265.99% | -132.30% | -138.58% | 67.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.19% | -265.99% | -132.30% | -138.58% | 67.85% |
| EBIT | -123.74% | -238.53% | -115.30% | -140.36% | 58.20% |
| EBITDA | -123.50% | -238.66% | -115.38% | -140.45% | 58.21% |
| EPS Basic | -33.80% | -138.77% | -115.98% | -74.71% | 78.37% |
| Normalized Basic EPS | -33.80% | -138.78% | -115.99% | -74.72% | 74.75% |
| EPS Diluted | -33.80% | -138.77% | -115.98% | -74.71% | 78.37% |
| Normalized Diluted EPS | -33.80% | -138.78% | -115.99% | -74.72% | 74.75% |
| Average Basic Shares Outstanding | 72.80% | 53.29% | 7.56% | 36.56% | 48.59% |
| Average Diluted Shares Outstanding | 72.80% | 53.29% | 7.56% | 36.56% | 48.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |